- Home
- LICN vs SLRX Comparison
LICN vs SLRX Comparison
Compare LICN & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICN
- SLRX
- Stock Information
- Founded
- LICN 2004
- SLRX N/A
- Country
- LICN China
- SLRX United States
- Employees
- LICN N/A
- SLRX N/A
- Industry
- LICN
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- LICN
- SLRX Health Care
- Exchange
- LICN Nasdaq
- SLRX Nasdaq
- Market Cap
- LICN 2.1M
- SLRX 1.7M
- IPO Year
- LICN 2023
- SLRX N/A
- Fundamental
- Price
- LICN $5.00
- SLRX $0.78
- Analyst Decision
- LICN
- SLRX
- Analyst Count
- LICN 0
- SLRX 0
- Target Price
- LICN N/A
- SLRX N/A
- AVG Volume (30 Days)
- LICN 1.7M
- SLRX 28.0K
- Earning Date
- LICN 01-01-0001
- SLRX 05-14-2025
- Dividend Yield
- LICN N/A
- SLRX N/A
- EPS Growth
- LICN N/A
- SLRX N/A
- EPS
- LICN N/A
- SLRX N/A
- Revenue
- LICN $41,477,000.00
- SLRX N/A
- Revenue This Year
- LICN N/A
- SLRX N/A
- Revenue Next Year
- LICN N/A
- SLRX N/A
- P/E Ratio
- LICN N/A
- SLRX N/A
- Revenue Growth
- LICN 4.32
- SLRX N/A
- 52 Week Low
- LICN $2.60
- SLRX $0.45
- 52 Week High
- LICN $488.00
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- LICN 50.79
- SLRX 49.77
- Support Level
- LICN $4.86
- SLRX $0.68
- Resistance Level
- LICN $6.16
- SLRX $0.84
- Average True Range (ATR)
- LICN 0.88
- SLRX 0.04
- MACD
- LICN -0.14
- SLRX 0.00
- Stochastic Oscillator
- LICN 20.77
- SLRX 18.40
About LICN Lichen China Limited
Lichen International Ltd formerly Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.